Caribou Biosciences Inc(CRBU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 6:40 PM ET (Korea 11/4 08:40)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.08 | Insider Own | 9% | Shs Outstand | 106.0M | Perf Week | -0.28% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | -22.42% | Insider Trans | - | Shs Float | 97.6M | Perf Month | -61.39% |
| Enterprise Value | -0.04B | PEG | - | EPS next Q | -0.26 | Inst Own | 46.13% | Short Float | 12.87% | Perf Quarter | -71.47% |
| Income | -0.10B | P/S | 4.91 | EPS this Y | 43.9% | Inst Trans | 11.78% | Short Ratio | 4.83 | Perf Half Y | -76.2% |
| Sales | 0.01B | P/B | 0.5 | EPS next 5Y | -2.05% | ROA | -56.87% | Short Interest | 12.55M | Perf YTD | -71.11% |
| Book/sh | 0.93 | P/C | 0.44 | EPS past 3/5Y | 1.01% -22.62% | ROE | -78.27% | 52W High | -87% ($3.54) | Perf Year | -81.09% |
| Cash/sh | 1.05 | P/FCF | - | Sales past 3/5Y | -6.95% -2.03% | ROIC | -83.81% | 52W Low | 12.05% ($0.41) | Perf 3Y | -89.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 39.66% | Gross Margin | 74.22% | Volatility(W/M) | 9.69% 11.15% | Perf 5Y | -97.99% |
| Dividend TTM | - | EV/Sales | -3.63 | Sales Y/Y TTM | 10.02% | Oper. Margin | -1090.9% | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.49 | EPS Q/Q | 58.66% | Profit Margin | -1030.42% | RSI (14) | 28.2 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.49 | Sales Q/Q | -43.79% | SMA20 | -5.77% ($0.49) | Beta | 2.48 | Target Price | $11 |
| Payout | - | Debt/Eq | 0.27 | Earnings | 2026/8/13 | SMA50 | -55.17% ($1.03) | Rel Volume | 0.53 | Prev Close | $0.44 |
| Employees | 97 | LT Debt/Eq | 0.26 | EPS/Sales Surpr. | 25.93% -34.23% | SMA200 | -71.63% ($1.62) | Avg Volume(3M) | 2.60M | Price | $0.46 |
| IPO | 2021/7/23 | Option/Short | Yes/Yes | Trades | 3848 | Volume | 1,379,702 | Change | 4.43% |
🧬 Caribou Biosciences (CRBU) is a clinical-stage biotech company developing allogeneic cell therapies based on gene editing. Leveraging its proprietary chRDNA gene-editing platform, the company develops T-cell therapy candidates targeting hematologic cancers and autoimmune diseases, and is headquartered in California, USA.
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
CRBU has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +43.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $491. Peers typically go for $931.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 46.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #416 of 597 in the industry
Based on market cap of $49M.
GANX#413 Gain Therapeutics Inc $50M PER - 
IBIO#414 iBio Inc $50M PER - 
ONCY#415 Oncolytics Biotech Inc $50M PER - CRBU#416 Caribou Biosciences Inc $49M PER - 
CNTB#417 Connect Biopharma Holdings Ltd $49M PER - 
FAQ
What kind of company is CRBU?
CRBU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRBU?
The market cap of CRBU is approximately $49M, ranking 4,847 within its sector.
What is the 52-week high and low for CRBU?
CRBU has recorded a 52-week high of $3.54 and a low of $0.41.
